Cancer
Glioma
胶质瘤
Tumours of the brain and spinal cord that arise from glial cells. They can be benign or malignant; glioblastoma is one type.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 187
- cities
- 67
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 32% of the world's English-language research papers on glioma, 2021–2025 (24% in 2016–2020), and 10% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
187 hospitals in 67 cities
Order: papers led on glioma, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 8 papers or 1 trial on glioma, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens glioma in that city. 57 more cities are in the menu below.
- 307 papers led
- 169 papers led
- 158 papers led
- 122 papers led
- 106 papers ledNo open trial led
- 82 papers led
- 78 papers led
- 72 papers led
- 71 papers ledNo open trial led
- 70 papers ledNo open trial led
- 66 papers led
- 63 papers ledNo open trial led
- 62 papers led
- 61 papers ledNo open trial led
- 61 papers led
- 60 papers ledNo open trial led
- 59 papers ledNo open trial led
- 56 papers led
- 56 papers led
- 56 papers led
- 54 papers ledNo open trial led
- 53 papers ledNo open trial led
- 53 papers led
- 52 papers ledNo open trial led
- 52 papers led
- 50 papers ledNo open trial led
- 47 papers led
- 46 papers led
- 44 papers ledNo open trial led
- 44 papers ledNo open trial led
- 43 papers ledNo open trial led
- 41 papers led
- 40 papers ledNo open trial led
- 39 papers ledNo open trial led
- 39 papers led
- 39 papers ledNo open trial led
- 38 papers ledNo open trial led
- 35 papers ledNo open trial led
- 32 papers ledNo open trial led
- 32 papers ledNo open trial led
- 32 papers ledNo open trial led
- 31 papers ledNo open trial led
- 31 papers ledNo open trial led
- 31 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers led
- 29 papers ledNo open trial led
- 28 papers ledNo open trial led
- 26 papers led
- 26 papers ledNo open trial led
- 26 papers ledNo open trial led
- 25 papers led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 24 papers ledNo open trial led
- 24 papers ledNo open trial led
- 24 papers led
- 23 papers ledNo open trial led
- 23 papers led
- 22 papers ledNo open trial led
- 22 papers ledNo open trial led
- 22 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 59
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 436 papers led6 hospitals
- 228 papers led6 hospitals
- 216 papers led6 hospitals
- 192 papers led4 hospitals
- 186 papers led6 hospitals
- 176 papers led6 hospitals
- 174 papers led6 hospitals
- 154 papers led6 hospitals
- 151 papers led5 hospitals
- 148 papers led6 hospitals
- 143 papers led6 hospitals
- 141 papers led3 hospitals
- 136 papers led6 hospitals
- 123 papers led6 hospitals
- 122 papers led4 hospitals
- 120 papers led6 hospitals
- 113 papers led5 hospitals
- 109 papers led4 hospitals
- 96 papers led6 hospitals
- 96 papers led6 hospitals
- 92 papers led6 hospitals
- 91 papers led3 hospitals
- 90 papers led6 hospitals
- 88 papers led3 hospitals
- 87 papers led6 hospitals
- 73 papers led6 hospitals
- 71 papers led5 hospitals
- 68 papers led3 hospitals
- 68 papers led6 hospitals
- 65 papers led3 hospitals
- 63 papers led1 hospital
- 61 papers led6 hospitals
- 56 papers led1 hospital
- 53 papers led6 hospitals
- 50 papers led3 hospitals
- 50 papers led5 hospitals
- 47 papers led6 hospitals
- 45 papers led6 hospitals
- 42 papers led4 hospitals
- 42 papers led6 hospitals
- 41 papers led6 hospitals
- 40 papers led6 hospitals
- 39 papers led3 hospitals
- 38 papers led1 hospital
- 34 papers led3 hospitals
- 33 papers led6 hospitals
- 28 papers led1 hospital
- 26 papers led1 hospital
- 26 papers led5 hospitals
- 20 papers led5 hospitals
- 20 papers led1 hospital
- 19 papers led2 hospitals
- 16 papers led6 hospitals
- 15 papers led1 hospital
- 11 papers led3 hospitals
- 10 papers led1 hospital
- 7 papers led1 hospital
- 6 papers led1 hospital
- 5 papers led1 hospital
open trials on glioma in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 74 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingA Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07243340
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07297212
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Shanghai, Shenzhen, Wuhan
- RecruitingSymptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07450872
Age 8 years to 18 years (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingDual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glioma
- Phase
- Phase 1
- Started
- 2026-02
- Posted
- Registry
- NCT07480941
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingA Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07501559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingProphylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07511725
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingDual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07551336
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingNK Cell Therapy for Malignant Solid Brain Tumors
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07552233
Age 18 years to 70 years (registered criteria)
Led by Peking University Third Hospital; 1 listed hospital as study siteBeijing, Zhengzhou
- RecruitingSub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07552467
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingPhase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07584499
Age 2 years to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07589257
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingMulticenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07608003
Age not stated (registered criteria)
Led by Xiangya HospitalChangsha
- RecruitingDosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07648823
Age 18 years to 80 years (registered criteria)
Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing
- Recruiting[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07655869
Age 18 years to Not stated (registered criteria)
Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07678684
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07710690
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesShanghai, Wuhan, Xi'an
- RecruitingA Phase I Clinical Study of YN003 in the Treatment of Glioma
- Phase
- Phase 1
- Started
- 2026-10
- Posted
- Registry
- NCT07929909
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingProspective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular Classification
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07940231
Age 18 years to Not stated (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- Recruiting5-Aminolevulinic Acid for Photodynamic Diagnosis of Malignant Glioma
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06160492
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Phase 2 Study of HX301 in Patients with High-grade Giloma
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06703255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingBC008-1A Injection for Recurrent CNS WHO G4 Glioma
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06773481
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEvaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06818331
Age 18 years to 70 years (registered criteria)
Led by Third Affiliated hospital of Zhejiang Chinese Medical University; 1 listed hospital as study siteHangzhou
- RecruitingClinical Study of Carbon Ion Radiotherapy for High-grade Glioma
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06831773
Age 14 years to 80 years (registered criteria)
Led by Gansu Wuwei Tumor HospitalWuwei
- RecruitingSafety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06902350
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changchun
- RecruitingPET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06914427
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingEnhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06936046
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPhase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07025018
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingClinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
- Phase
- Early phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07067905
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07093814
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shenzhen, Xi'an, Zhuhai
- RecruitingAllogeneic γδT Cells in Glioblastoma
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT07144735
Age 18 years to 70 years (registered criteria)
Led by Peking University Third Hospital; 1 listed hospital as study siteBeijing, Zhengzhou
- RecruitingB7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
- Phase
- Phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07193628
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07193654
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAI-assisted Diagnosis of Malignant Brain Tumors
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07198256
Age 18 years to 100 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou
- RecruitingProspective Real-World Study of Pathology AI for Glioma Molecular Prediction
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07263711
Age 18 years to 100 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07306299
Age 16 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingConstruction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07405372
Age 18 years to Not stated (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- RecruitingEvaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
- Phase
- Early phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT07538128
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingIntensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07670026
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingResearch on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
- Phase
- N/A
- Started
- 2024-05
- Posted
- Registry
- NCT05990556
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingA Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial
- Phase
- N/A
- Started
- 2024-02
- Posted
- Registry
- NCT06215495
Age 18 years to 65 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingEvaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06327451
Age 18 years to 60 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingEffect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma
- Phase
- Phase 3
- Started
- 2024-04
- Posted
- Registry
- NCT06330337
Age 18 years to 70 years (registered criteria)
Led by Third Affiliated hospital of Zhejiang Chinese Medical University; 1 listed hospital as study siteHangzhou
- RecruitingSafety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06482905
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of BL-B01D1 in Patients With Recurrent Glioblastoma
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06598787
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingHypofractionated Radiotherapy
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06740955
Age 18 years to 70 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingBevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06747728
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingSafety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients
- Phase
- Early phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06757153
Age 18 years to Not stated (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingA Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma
- Phase
- Phase 1/Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT07599371
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingSIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05303519
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Shanghai
- RecruitingTris-CAR-T Cell Therapy for Recurrent Glioblastoma
- Phase
- Phase 1
- Started
- 2023-09
- Posted
- Registry
- NCT05577091
Age 18 years to 70 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingGenetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT05672043
Age 0 years to 18 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingOncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
- Phase
- Phase 1
- Started
- 2023-01
- Posted
- Registry
- NCT05717699
Age 1 year to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingOncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
- Phase
- Phase 1
- Started
- 2023-01
- Posted
- Registry
- NCT05717712
Age 1 year to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingDetection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
- Phase
- Not given
- Started
- 2023-09
- Posted
- Registry
- NCT05968053
Age 18 years to 80 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingMulti-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
- Phase
- Not given
- Started
- 2023-09
- Posted
- Registry
- NCT06002711
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingClinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
- Phase
- Phase 1/Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT06018363
Age 18 years to 70 years (registered criteria)
Led by Fourth Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingTumor Vaccines for Solid Tumors
- Phase
- Not given
- Started
- 2023-10
- Posted
- Registry
- NCT06102837
Age not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingThe Effects of Anesthetics on Brain Network Connectivity in Patients With Supratentorial Glioma
- Phase
- Not given
- Started
- 2023-08
- Posted
- Registry
- NCT06138340
Age 18 years to Not stated (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingThe Role of B7-H4 in Tumor Vaccine
- Phase
- Not given
- Started
- 2023-11
- Posted
- Registry
- NCT06156150
Age 18 years to 80 years (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingRecurrent High Grade Glioma Treated by LITT
- Phase
- N/A
- Started
- 2023-09
- Posted
- Registry
- NCT06161610
Age 18 years to Not stated (registered criteria)
Led by Beijing Tiantan Hospital; 7 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Shanghai, Wuhan, Zhengzhou
- RecruitingThe Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06220552
Age 18 years to Not stated (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingClinical Study of Oncolytic Virus in Glioblastoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT07145047
Age 18 years to 70 years (registered criteria)
Led by Mianyang Central HospitalMianyang
- RecruitingSintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
- Phase
- Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05512351
Age 18 years to Not stated (registered criteria)
Led by Henan Provincial People's HospitalZhengzhou
- RecruitingClinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
- Phase
- Not given
- Started
- 2022-01
- Posted
- Registry
- NCT05859659
Age 18 years to 90 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingA Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
- Phase
- Not given
- Started
- 2022-05
- Posted
- Registry
- NCT06173076
Age 18 years to 100 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingJK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
- Phase
- Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT06595186
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Registry-Based Cohort Study on the Clinical Outcomes of Spinal Cord Glioma Resection Via the Dorsolateral Sulcus Approach
- Phase
- Not given
- Started
- 2022-01
- Posted
- Registry
- NCT07066475
Age 3 years to 75 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingA Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2021-04
- Posted
- Registry
- NCT04794972
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Shenzhen, Xi'an
- RecruitingStudy of GC101 TIL in Brain Glioma (Soochow2)
- Phase
- Early phase 1
- Started
- 2021-05
- Posted
- Registry
- NCT04943913
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingRadiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery
- Phase
- Phase 2/Phase 3
- Started
- 2018-04
- Posted
- Registry
- NCT04316039
Age 18 years to 70 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingMR Based Survival Prediction of Glioma Patients Using Artificial Intelligence
- Phase
- Not given
- Started
- 2017-01
- Posted
- Registry
- NCT04215211
Age 1 year to 90 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingHistopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence
- Phase
- Not given
- Started
- 2017-01
- Posted
- Registry
- NCT04215224
Age 1 year to 90 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingMR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
- Phase
- Not given
- Started
- 2017-01
- Posted
- Registry
- NCT04217018
Age 1 year to 95 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingHistopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
- Phase
- Not given
- Started
- 2017-01
- Posted
- Registry
- NCT04217044
Age 1 year to 95 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingMagnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion
- Phase
- N/A
- Started
- 2017-01
- Posted
- Registry
- NCT05990244
Age 18 years to 80 years (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingIntegrative Analysis of Human Glioblastoma Multiforme
- Phase
- Not given
- Started
- 2016-01
- Posted
- Registry
- NCT03005132
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingAmino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
- Phase
- Not given
- Started
- 2013-08
- Posted
- Registry
- NCT07379463
Age 18 years to 90 years (registered criteria)
Led by Tianjin Medical University General Hospital; 2 listed hospitals as study sitesHefei, Qingdao, Tianjin
- Not yet recruitingA Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07455045
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingVorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07469735
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- Not yet recruitingA Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07472790
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingIL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07481721
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingEEG-Guided Cognitive Function Preservation in Patients With Brain Tumors
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07699172
Age 18 years to 75 years (registered criteria)
Led by Tianjin Huanhu HospitalTianjin
- Not yet recruitingLevetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07758062
Age 18 years to 69 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- Not yet recruitingEntacapone Plus Bevacizumab for Glioblastoma at First Recurrence
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07831187
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- Not yet recruitingIMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma
- Phase
- Phase 3
- Started
- 2026-12
- Posted
- Registry
- NCT07869524
Age 3 years to 18 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- Not yet recruitingTris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
- Phase
- Phase 2/Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07873996
Age 18 years to 65 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- Not yet recruitingStudy of MT027 in Patients with Recurrent or Progressive High-grade Glioma
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06737146
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingPhotodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT06939400
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Provincial People's HospitalHangzhou
- Not yet recruitingFCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07004075
Age 2 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingPhase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07020052
Age 3 years to 18 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingSafety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
- Phase
- Early phase 1
- Started
- 2025-11
- Posted
- Registry
- NCT07244666
Age 19 years to 70 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingSub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06368934
Age 18 years to 80 years (registered criteria)
Led by Huashan Hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingClinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
- Phase
- Early phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06396481
Age 4 years to Not stated (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- Not yet recruitingTislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT05540275
Age 18 years to Not stated (registered criteria)
Led by Henan Provincial People's HospitalZhengzhou
- Not yet recruitingElemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
- Phase
- Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT05842746
Age 18 years to 70 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingSintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
- Phase
- Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05502991
Age 18 years to Not stated (registered criteria)
Led by Henan Provincial People's HospitalZhengzhou
- Not yet recruitingStudy on Gene Evolution in Glioma Under Stress Therapy
- Phase
- Not given
- Started
- 2022-12
- Posted
- Registry
- NCT05512325
Age 18 years to 75 years (registered criteria)
Led by Henan Provincial People's HospitalZhengzhou
- Not yet recruitingCorrelation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma
- Phase
- Not given
- Started
- 2022-12
- Posted
- Registry
- NCT05532969
Age 18 years to 75 years (registered criteria)
Led by Henan Provincial People's HospitalZhengzhou
- Not yet recruitingRadiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
- Phase
- Not given
- Started
- 2022-12
- Posted
- Registry
- NCT05541042
Age 18 years to Not stated (registered criteria)
Led by Henan Provincial People's HospitalZhengzhou
- Enrolling by invitationClinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT07126990
Age 18 years to 80 years (registered criteria)
Led by Sanbo Brain HospitalBeijing
- Enrolling by invitationEvaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06690216
Age 18 years to Not stated (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- Enrolling by invitationEvaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06763965
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Enrolling by invitationThe Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
- Phase
- Phase 1
- Started
- 2023-12
- Posted
- Registry
- NCT06616727
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Additional research sources
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.